LivaNova - Page title

Miscellaneous

May 3, 2016

03 May 2016

LIVANOVA PLC

Filing of preliminary proxy statement on Schedule 14A with the US Securities and Exchange Commission

LivaNova PLC (the "Company") announces today that it has filed its preliminary proxy statement on Schedule 14A with the US Securities and Exchange Commission ("SEC"). The document is available for viewing on the SEC website and also on the Company's website at www.livanova.com.

A copy of the preliminary proxy statement on Schedule 14A has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at www.morningstar.co.uk/uk/NSM.

About LivaNova

LivaNova PLC, headquartered in London, U.K., is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media:
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com